A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumoursGabriel Mak, Hendrik‐Tobias Arkenau, Ronald A. Fleming et al.|British Journal of Cancer|2019Cited by 103
A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors.Hendrik‐Tobias Arkenau, Li Yan, Anas Gazzah et al.|Journal of Clinical Oncology|2015Cited by 7